Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC

 

Abstract No : 9518

Abstract Type : Poster Discussion Session

Indication : ALK+ NSCLC

Intervention : Alectinib (ALC) versus crizotinib (CRZ)

Company : F. Hoffman-La Roche Ltd

Technology : Small molecule

 

Results:

This is the first global randomized study of a 2nd generation ALK TKI to demonstrate a clinically meaningful improvement in OS vs CRZ in ALK+ NSCLC (5-year survival rate: 62.5%, ALC vs 45.5%, CRZ); longer FU is required as OS data remain immature.

 

Conclusion:

Around 62.5% patients are still alive at 5 years on alectinib compared to 45.5% in first crizotinib (CRZ) in the global randomized study which will further strengthen the position of first line usage of alectinib

 

Commentary:

Roche presented long term data of alectinib from ALEX study in frontline advanced ALK+ NSCLC.

The therapeutics segment is experiencing significant NSCLC clinical trial activity, which is further expected to drive Non-Small Cell Lung Caner market growth in the coming years.

Refer to ALK positive NSCLC Market report for detailed Insights.